Calder Biosciences is at the forefront of vaccine development, utilizing its proprietary 3D-Vaxlock™ technology to create conformationally stabilized prefusion subunit vaccines. This innovative approach involves engineering site-specific, covalent crosslinks within viral proteins, effectively locking them in their most potent three-dimensional shapes. By maintaining the structural integrity of these proteins, Calder aims to elicit robust immune responses against various viral pathogens, including Respiratory Syncytial Virus (RSV), seasonal and pandemic influenza, and Epstein-Barr Virus (EBV). The technology not only enhances the stability and efficacy of the vaccines but also reduces the need for stringent cold-chain storage, making it a cost-effective solution for global health challenges.

The company's vaccine pipeline includes several promising candidates, such as the RSV DT-preF vaccine, which is designed to maintain the prefusion conformation of the RSV F protein, thereby improving its immunogenicity. Additionally, Calder is developing a universal influenza vaccine that targets the conserved stalk domain of the hemagglutinin protein, aiming to provide broad protection against multiple influenza strains. The EBV vaccine program focuses on stabilizing key viral proteins to generate potent neutralizing antibody responses. Through collaborations with leading researchers and institutions, Calder is committed to addressing significant health issues posed by viral infections, leveraging its advanced bioprocess technology to create effective and durable vaccines.

United States

Calder Biosciences, Inc. is a nano-scale molecular engineering company that is applying its platform technology to develop novel respiratory syncytial virus (RSV) and universal Influenza vaccines that both represent multi-billion dollar market opportunities with mitigated clinical risk.

Calder Biosciences

Company Details